2-OH(E1+E2) / 16α-OHE1 Ratio

Maybe you're weighing a supplement that promises to steer estrogen down a safer path, or you've seen a 2/16 number on a hormone report and don't know what to make of it. This ratio comes from research behind those claims, but most of that research studied a different calculation. This version adds urinary 2-hydroxyestrone and 2-hydroxyestradiol, then divides their sum by urinary 16α-hydroxyestrone.

It's an exploratory marker of estrogen metabolism. Published associations haven't established this exact ratio as a way to predict your individual cancer risk, choose a hormone dose, or judge whether a supplement will improve your health. There is no outcome-validated optimal target.

What the Ratio Describes

Estrone is abbreviated E1. Estradiol is abbreviated E2. Estrone becomes the predominant circulating estrogen after menopause, while estradiol is the more potent estrogen and predominates during the reproductive years. Your liver and other tissues change these hormones into products that can undergo further processing and leave the body.

Some of these chemical changes occur at positions called 2, 4, and 16α on the estrogen molecule. The products are called estrogen metabolites. This ratio compares selected products from the 2 and 16α routes; it leaves out the 4 route and several other products.

The original theory was that favoring the 2 route would reduce estrogen's effects on breast tissue. In experiments using human breast cancer cells grown in a laboratory, 16α-hydroxyestrone stimulated estrogen responses, while the 2-hydroxy products showed weaker or opposing effects in some assays. These cell experiments don't establish that a higher urinary ratio prevents cancer in people.

A higher result means there is more of the combined 2-hydroxy products relative to 16α-hydroxyestrone in your urine. It can rise because the top of the ratio increases, the bottom decreases, or both. The same ratio can occur with very different amounts of all three compounds. It doesn't measure the amount of active estrogen reaching your breast, prostate, or bones.

The compounds are measured in a 24-hour urine collection using liquid chromatography-tandem mass spectrometry, abbreviated LC-MS/MS. This method separates compounds and identifies them using their mass and characteristic fragments. The resulting ratio has no units.

Most older studies reported 2-hydroxyestrone divided by 16α-hydroxyestrone, without adding 2-hydroxyestradiol. Other studies added together many products from each pathway. Those calculations concern related biology, but their numbers and findings cannot be applied directly to this combined ratio.

Breast Cancer and the 2/16 Theory

Prospective studies collected samples before breast cancer developed. They have produced inconsistent findings, even before accounting for the differences between blood and urine, collection schedules, and laboratory methods.

A combined analysis of five studies using the older urinary E1-only ratio found no clear association with breast cancer before or after menopause. A separate pooled analysis of about 2,800 postmenopausal women found that more extensive 2-pathway metabolism was associated with lower risk when total estrogen was taken into account. That analysis combined blood and urine studies and examined broader pathway measures, including a ratio that summed more compounds than this test does.

These differences remain unresolved. They show why a laboratory theory about weaker and stronger estrogen products isn't enough to turn this result into a personal cancer-risk score.

Survival After a Breast Cancer Diagnosis

One study followed 683 women with breast cancer for a median of nearly 18 years. It used spot urine collected after diagnosis and an antibody-based E1-only ratio. Women above the study's median ratio had a lower rate of death from any cause in an adjusted analysis.

The association was stronger among women who had already received chemotherapy before collection, so treatment may have influenced what the urine measurement represented. This was an observational finding. No trial has shown that raising this ratio improves survival, and the study didn't validate the combined 24-hour ratio for monitoring recovery or recurrence.

Prostate Cancer in Men

A small pooled analysis of urinary studies found about half the odds of prostate cancer among men in the highest third of the E1-only ratio compared with the lowest third. The highest third of 16α-hydroxyestrone had about 1.8 times the odds. These were antibody-based measurements, with collection protocols that differed from this 24-hour LC-MS/MS test.

A separate study of aggressive prostate cancer found a higher serum E1-only ratio associated with higher risk. Serum and urine reflect different aspects of estrogen metabolism. Neither finding establishes a way to estimate your prostate cancer risk from this combined urinary ratio.

Bone Density and Blood Pressure

In a study of 71 postmenopausal women followed for a year, higher urinary E1-only ratios and some other 2-pathway products were associated with lower bone density or greater bone loss. Women with the lowest ratios had no measured bone loss during that follow-up. The study was small and didn't establish that changing estrogen breakdown would protect or harm bone.

In a separate cross-sectional study of 80 postmenopausal women, a higher urinary E1-only ratio was associated with lower systolic blood pressure after adjustment for other factors. Systolic pressure is the top number in a blood pressure reading. This study compared measurements taken around the same time; it didn't show that raising the ratio lowers blood pressure.

Other Research on Estrogen Metabolism

A study of women carrying BMPR2 gene variants compared five who had pulmonary arterial hypertension with six who did not. The affected women had a substantially lower antibody-measured urinary 2/16 ratio than the unaffected carriers. This very small comparison used a related measurement and has not established a role for this combined ratio in screening or monitoring inherited pulmonary hypertension.

Genetic differences can influence estrogen breakdown without making the ratio a fixed genetic result. Premenopausal women carrying CYP3A7*1C had lower urinary 2-pathway products and lower related ratios in a study using timed spot samples. Another small study linked greater gut microbial diversity with more urinary estrogen metabolites relative to parent estrogens. That calculation was different from this ratio and didn't establish that changing gut bacteria changes your result or disease risk.

When Results Can Be Misleading

• Hormones and supplements: estrogen treatment, hormonal contraception, and estrogen-focused supplements can change the production or processing of hormones. A result during treatment represents that setting and may differ from your untreated pattern.
• Menstrual timing: estrogen production and urinary metabolite patterns vary across the cycle. Samples from different phases can be difficult to compare.
• A different formula or method: an E1-only ratio, a broader pathway ratio, and this combined ratio are different measurements. Older antibody-based assays can also give different results from LC-MS/MS, especially after menopause.
• Very small component amounts: LC-MS/MS still has detection limits and analytical variation. When 16α-hydroxyestrone is close to the detection limit, a small change in it can produce a large change in the ratio. A calculated value is less informative when a component can't be measured reliably.
• An incomplete or poorly stored collection: missed urine, collection over the wrong interval, or failure to follow storage instructions can make the specimen unrepresentative. Dividing two measurements from the same container doesn't correct these problems.

What a Trend Can Show

A study of repeated, mostly first-morning urine samples in premenopausal women found that several estrogen metabolites and the E1-only ratio were reasonably reproducible over two to three years. That supports their use in research, but it doesn't mean every change between two results is a biological change. It also doesn't establish how much change in this combined 24-hour ratio would matter for your health.